Sign In

​Visit for updates to this and other sections of the guidance., a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the treatment of hepatitis C (HCV), has released updates on several sections of the website based on newly available therapies and data.

The latest release of the guidance reflects several important developments, including the recent approval of the second single-tablet fixed dose combination regimen (elbasvir/grazoprevir) for the treatment of HCV. Based on the approval of this regimen, the website now also includes guidance on the role of testing for resistance to some HCV medications that may exist in patients prior to starting therapy.

While most sections of the guidance have been updated, the most significant changes have been made in the Initial Treatment of HCV Infection and Retreatment of Persons in Whom Prior Treatment Has Failed sections as well as the Unique Populations sections, which include patients living with HIV, kidney disease, and severe liver disease including those with severe liver dysfunction and those who have had a liver transplant. Updated references have been provided throughout the guidance.

Visit for updates to this and other sections of the guidance.


AASLD is a medical subspecialty society representing clinicians and researchers in liver disease. The work of our members has laid the foundation for the development of drugs used to treat patients with viral hepatitis. Access to care and support of liver disease research are at the center of AASLD’s advocacy efforts.

AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. AASLD was founded in 1950 by a small group of leading liver specialists and has grown to an international society responsible for all aspects of hepatology.

About IDSA

The Infectious Diseases Society of America (IDSA) is an organization of physicians, scientists, and other health care professionals dedicated to promoting health through excellence in infectious diseases research, education, prevention, and patient care. The Society, which has nearly 10,000 members, was founded in 1963 and is based in Arlington, VA. For more information, see

Visit to access IDSA’s extensive collection of resources on hepatitis C, including the Society’s Core Curriculum for HCV.